Kapanol sold to Mayne
December 17, 2012
GLAXOSMITHKLINE has sold
Kapanol and related assets to
Mayne Pharma in a deal worth up
to $14m (PD Breaking News 14 Dec).
Kapanol is a modified release oral
opioid used for the relief of chronic,
moderate to severe pain, and
currently represents 6% of the
A$90 million modified release oral
opioid analgesic market.
Under the terms of the
agreement, Mayne Pharma will
acquire the Kapanol trademark,
marketing authorisations, product
dossier, technical data and product
inventory, whilst the existing
license arrangement between
Mayne Pharma and GSK will be
amended so that Mayne Pharma
will acquire the rights to sell
Kapanol in Australia.
For the 12 months to 31 October
2012, Kapanol generated gross
sales of A$5.5 million in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Dec 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Dec 12
